Why Herceptin isn't perfect

As with many drugs, fatal adverse events have been detected during postmarketing surveillance of Genentech Inc.'s Herceptin trastuzumab anti-HER2 monoclonal antibody to treat breast cancer. While such side effects were not seen in the company's clinical trials, DNA does not believe that the

Read the full 435 word article

How to gain access

Continue reading with a
two-week free trial.